Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Phase 1/2 Recruiting
316 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
ASPEN-09-03
Phase 2 Recruiting
120 enrolled
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Phase 3 Recruiting
840 enrolled
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Phase 3 Recruiting
1,800 enrolled
MOUNTAINEER-03
Phase 3 Recruiting
400 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
1,000 enrolled
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Phase 2 Recruiting
30 enrolled
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Phase 3 Recruiting
544 enrolled
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Phase 3 Recruiting
726 enrolled
EmpowHER 208
Phase 2 Recruiting
125 enrolled
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Phase 3 Recruiting
550 enrolled
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3 Recruiting
540 enrolled
DG-03
Phase 2 Recruiting
450 enrolled
MK-1022-009
Phase 1/2 Recruiting
81 enrolled
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Phase 3 Recruiting
550 enrolled
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Phase 3 Recruiting
740 enrolled
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 3 Recruiting
555 enrolled
PIKture-01
Phase 1 Recruiting
200 enrolled
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 1/2 Recruiting
18 enrolled
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Phase 3 Recruiting
880 enrolled
Neo-Healer
Phase 3 Recruiting
520 enrolled
Zotatifin
Phase 1/2 Recruiting
30 enrolled